Xanthohumol as a potential therapeutic strategy for acute myeloid leukemia: Targeting the FLT3/SRPK1 signaling axis.

ABSTRACT: Xanthohumol (XN) is an isoprene chalcone found in hops (Humulus lupulus L.), a food ingredient with a wide range of pharmacological activities. The aim of this study was to reveal the therapeutic effect of XN on acute myeloid leukemia (AML) and the potential underlying molecular mechanism. Through network pharmacology analysis, molecular docking, and HTRF determination, XN was shown to inhibit the kinase activities of FLT3 and SRPK1 by targeting their ATP-binding domains, with IC₅₀ values of 1.51 ± 0.44 μM and 0.37 ± 0.15 μM, respectively. By inhibiting AML cell proliferation, promoting apoptosis, regulating autophagy, and inhibiting invasion, XN, which targets the unique FLT3/SRPK1 signaling pathway, exerts anti-AML effects. XN also significantly inhibited FLT3 inhibitor-resist

SUBMITTER: Zhang DN 

PROVIDER: S-EPMC12039533 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature